Granulomatosis with Polyangiitis clinical trials
The registry lists 104 studies for Granulomatosis with Polyangiitis across more than 10 countries. 16 are recruiting or about to start. 56 of them are mainly about Granulomatosis with Polyangiitis (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-20.
Get an email when these change. Save the Granulomatosis with Polyangiitis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Institute of Allergy and Infectious Diseases (NIAID) (12) · Assistance Publique - Hôpitaux de Paris (11) · University of Pennsylvania (11) · University of South Florida (7) · Cambridge University Hospitals NHS Foundation Trust (4) · Novartis Pharmaceuticals (2) · Hoffmann-La Roche (2) · Chiba University (2)
What is being tested here
Drugs under test in Granulomatosis with Polyangiitis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Rituximab | 4 | 6 | 16 |
| Tofacitinib | 2 | 1 | 3 |
| Avacopan | 2 | 1 | 2 |
| Tocilizumab | 2 | 1 | 2 |
| Prednisone | 1 | 3 | 5 |
| Mycophenolic Acid | 1 | 1 | 4 |
| Abatacept | 1 | 1 | 4 |
| Cyclophosphamide | 1 | 2 | 4 |
| Methotrexate | 1 | 1 | 4 |
| Belimumab | 1 | 1 | 3 |
Drug classes tested here Corticosteroids 2 open · JAK inhibitors 2 open · Tyrosine kinase inhibitors (TKIs) 2 open · Antimetabolites 1 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3
- Dec 2026Iptacopan in Patients With ANCA Associated Vasculitis · Novartis Pharmaceuticals
- Mar 2027Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis · Chiba University
- Jul 2027Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases. · IRIS Research and Development, LLC
Who these studies take
Of the 15 Granulomatosis with Polyangiitis studies recruiting now, 11 (73%) set no upper age limit and 3 (20%) stop at 75 or younger. 6 (40%) take children under 18. 1 (7%) are for women only and 0 (0%) for men only; 2 (13%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 5 (33%) | 5 (33%) |
| 18 | 15 (100%) | 14 (93%) |
| 30 | 14 (93%) | 13 (87%) |
| 40 | 14 (93%) | 13 (87%) |
| 50 | 14 (93%) | 13 (87%) |
| 65 | 12 (80%) | 12 (80%) |
| 75 | 12 (80%) | 12 (80%) |
| 85 | 12 (80%) | 12 (80%) |
Across all 104 studies, recruiting or not: 13% stop at 75 or younger and 8% at 65; 30% take children; 2% are for women only and 1% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 104. Browse all 104 → or search them.
- TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With PolyangiitisRecruitingNCT07176546Phase 2/31 country
- Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic DiseasesRecruitingNCT07087912Phase 41 country
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingNCT07138898Phase 21 country
- Study of Salvage Therapy to Treat Patients With Granulomatosis With PolyangiitisRecruitingNCT04871191Phase 31 country
- Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With PolyangiitisRecruitingNCT06940661Phase 21 country
- Comparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis.Not yet recruitingNCT07451847Phase 41 country
- Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)RecruitingNCT06983821Phase 31 country
- Vasculitis Pregnancy RegistryRecruitingNCT025935651 country
- Clinical Transcriptomics in Systemic Vasculitis (CUTIS)RecruitingNCT030043262 countries
- VCRC Tissue RepositoryRecruitingNCT029670682 countries
- One-Time DNA Study for VasculitisRecruitingNCT012413053 countries
- Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated VasculitisRecruitingNCT06611696Phase 41 country
- Special Drug Use-results Survey for Long-term Use（Avacopan）RecruitingNCT067582711 country
- Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)RecruitingNCT06350110Phase 1/21 country
- Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.RecruitingNCT06581562Phase 11 country
- Pediatric Vasculitis InitiativeRecruitingNCT020061347 countries
- An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular DiseasesActive, not recruitingNCT05732402Phase 1/24 countries
- Iptacopan in Patients With ANCA Associated VasculitisActive, not recruitingNCT06388941Phase 215 countries
- TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With PolyangiitisActive, not recruitingNCT03919435Phase 1/21 country
- Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPAActive, not recruitingNCT06868290Phase 28 countries
- Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated VasculitisCompletedNCT03698071Not applicable1 country
- The Assessment of Prednisone In Remission Trial - Centers of Excellence ApproachCompletedNCT01940094Phase 32 countries
- Assessing Granulomatosis With Polyangiitis Activity: 18F-FDG PET/CT vs BVAS v3CompletedNCT077121721 country
- PR3-AAV Resilient Remission or PRRRTerminatedNCT05376319Phase 21 country
- Hydroxychloroquine in ANCA Vasculitis EvaluationTerminatedNCT04316494Phase 41 country
- Study of One Protein Implicated in Wegener DiseaseCompletedNCT01167491Not applicable1 country
- Low Dose Naltrexone to Improve Physical Health in Patients With VasculitisCompletedNCT03482479Phase 22 countries
- Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the OriginatorCompletedNCT057163341 country
- Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)Active, not recruitingNCT06294236Phase 11 country
- Comparison Between a Long Term and a Conventional Maintenance Treatment With RituximabCompletedNCT02433522Phase 31 country
- Efficacy Study of Two Treatments in the Remission of VasculitisCompletedNCT00748644Phase 31 country
- Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis)CompletedNCT018620681 country
- Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated VasculitisCompletedNCT01731561Phase 31 country
- Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)CompletedNCT00103792Phase 31 country
- The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric ApproachActive, not recruitingNCT01933724Phase 31 country
- Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)CompletedNCT02108860Phase 35 countries
- Establishment of an ELISA for the Recognition of Procalcitonin Variants in Patients With Hyperprocalcitonemia.CompletedNCT057038021 country
- PatientSpot Formerly Known as ArthritisPowerStatus unknownNCT038409281 country
- Urinary T Lymphocytes Predict Renal Flares in Patients With Inactive ANCA-associated GlomerulonephritisCompletedNCT044283981 country
- PRagmatic Analysis of Vitamin D in ANCA-Associated VasculitisCompletedNCT04280601Not applicable1 country
- Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.CompletedNCT03895801Phase 211 countries
- Urinary T Cell Biomarker for Prediction in ANCA GlomerulonephritisStatus unknownNCT043206672 countries
- Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener's) and Microscopic PolyangiitisCompletedNCT003153932 countries
- A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic PolyangitisCompletedNCT02115997Phase 41 country
- Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPATerminatedNCT03712345Phase 22 countries
- Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male VolunteersStatus unknownNCT05353179Early Phase 11 country
- Rituximab Vasculitis Maintenance StudyCompletedNCT01697267Phase 310 countries
- Rituximab and Belimumab Combination Therapy in PR3 VasculitisStatus unknownNCT03967925Phase 21 country
- Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory DiseasesCompletedNCT01988506Phase 21 country
- Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPAStatus unknownNCT04944524Phase 41 country